Search results
Results from the WOW.Com Content Network
Since November 2023, CRISPR Therapeutics has been earning approvals for Casgevy, a gene-editing medicine, in various countries and regions. This new coverage could also make it easier once CRISPR ...
CRISPR Therapeutics recently hit a breakthrough point when it earned approval for its first product, Casgevy, a therapy for sickle cell disease and transfusion-dependent beta-thalassemia.
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $119, marking a -0.63% move from the previous day. CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should ...
CRISPR Therapeutics (NASDAQ: CRSP) isn't a stock that's wanting for reasons to invest. Per the company's presentation at the American Society of Hematology's (ASH) annual meeting on Dec. 9, the ...
ZUG, Switzerland and BOSTON, Nov. 05, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today reported financial results for the third quarter ended September 30, 2024.
CRISPR Therapeutics AG (CRSP) closed at $67.66 in the latest trading session, marking a +0.71% move from the prior day.
CRISPR Therapeutics AG (CRSP) closed at $57.76 in the latest trading session, marking a +1.33% move from the prior day.
In the latest trading session, CRISPR Therapeutics AG (CRSP) closed at $62.43, marking a +0.02% move from the previous day.